Next |
home / stock / svra / svra message board
Subject | By | Source | When |
---|---|---|---|
Impala must be doing better ... hod $2.82 | AKAPAK | investorshub | 01/26/2023 5:46:22 PM |
Wake up call to the board $2.47 | AKAPAK | investorshub | 01/25/2023 6:35:04 PM |
Finally done dumping on the new financials. | Mrfairfield | investorshub | 05/14/2021 1:57:56 PM |
Looking for comments, | 20stockman20 | investorshub | 03/23/2021 2:32:06 PM |
Wow looks like dump is still on imo | Roadtojourney | investorshub | 03/22/2021 7:23:04 PM |
Check out what BARCHART has to say about $SVRA | 20stockman20 | investorshub | 03/20/2021 5:45:44 PM |
jumped in, looks good to me | 20stockman20 | investorshub | 03/18/2021 3:11:46 PM |
Savara Inc Stock may give you a sharp | lecorb | investorshub | 03/18/2021 5:05:40 AM |
Not really, had 120 million volume yesterday | Klinsmann | investorshub | 03/17/2021 2:40:02 PM |
The volume today should say it all, surpassed | ronjon41 | investorshub | 03/17/2021 2:36:12 PM |
Looks like they still at it | maximumgriff | investorshub | 03/17/2021 12:52:51 PM |
This is one you need for long term. | Jess070283 | investorshub | 03/17/2021 12:27:54 PM |
Corrupt MM's manipulation brought it down from the | trendzone | investorshub | 03/17/2021 11:31:45 AM |
Jep, 100% agree. It traded volume of a | Klinsmann | investorshub | 03/17/2021 7:33:48 AM |
Closed a massive 130 mill Offering! Check out | maximumgriff | investorshub | 03/17/2021 12:41:13 AM |
* * $SVRA Video Chart 03-16-2021 * * | ClayTrader | investorshub | 03/16/2021 8:07:25 PM |
znewcar1: SVRA 24% v1,3M c1.97 f54,1M H2 | znewcar1 | investorshangout | 02/04/2021 11:11:31 PM |
In the money Jan. 6: Drug, burger makers | DMOST | investorshub | 01/07/2020 2:37:09 AM |
DMOST....."In Like Flint", look towards a hug | DMOST | investorshub | 01/07/2020 2:32:53 AM |
* * $SVRA Video Chart 01-02-2020 * * | ClayTrader | investorshub | 01/02/2020 10:10:18 PM |
News, Short Squeeze, Breakout and More Instantly...
Remains On-Track to Report Top Line Data from the Pivotal Phase 3 IMPALA-2 Trial by End of 2Q 2024 48-week placebo-controlled trial is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP)...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on March 14, 2024 at 5:00am PT/8:00am ET. A live web...
Savara Inc. (NASDAQ: SVRA) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 4.49% on the day to $5.35. Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candid...